A real-world study to assess the economic burden and clinical outcome in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece

被引：0
|
作者：
Karachalios, G. [1 ]
Gourgioti, R. [1 ]
Alexopoulou, A. [1 ]
Kourlaba, G. [2 ]
机构：
[1] Genesis Pharma SA, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Med Sch, Dept Intens Care A, Athens, Greece
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P278
引用
收藏
页码：309 / 310
页数：2
相关论文
共 50 条
  • [21] Dimethyl fumarate: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    Burness C.B.
    Deeks E.D.
    Drugs & Therapy Perspectives, 2014, 30 (9) : 303 - 308
  • [22] Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study
    Sloane, Jacob
    Phillips, J. Theodore
    Calkwood, Jonathan
    Van der Walt, Anneke
    Min, Jinny
    Wu, Fan
    Taylor, Catherine
    NEUROLOGY, 2018, 90
  • [23] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [24] EXTENDING THERAPEUTIC POSSIBILITIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: DIMETHYL FUMARATE
    Matolcsi Judit
    Rozsa Csilla
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2015, 68 (1-2): : 7 - 14
  • [25] Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Haenni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Oezguer
    JOURNAL OF NEUROLOGY, 2021, 268 (03) : 941 - 949
  • [26] Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis
    Saijo, Naoya
    Abe, Yu
    Oikawa, Yoshitsugu
    Okubo, Yukimune
    Endo, Wakaba
    Numata-Uematsu, Yurika
    Takahashi, Toshiyuki
    Uematsu, Mitsugu
    BRAIN & DEVELOPMENT, 2022, 44 (05): : 353 - 356
  • [27] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [28] Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis
    Singer, Barry A.
    Shafer, S. James
    Arnold, Douglas L.
    Bowen, James D.
    LaGanke, Christopher
    Chen, Hailu
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    Naismith, Robert T.
    NEUROLOGY, 2020, 94 (15)
  • [29] Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC
    Berger, T.
    Brochet, B.
    Brambilla, L.
    Giacomini, P. S.
    Montalban, X.
    Salgado, A. Vasco
    Su, R.
    Bretagne, A.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (04)
  • [30] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
12345